125 related articles for article (PubMed ID: 2318450)
21. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
Yedema C; Massuger L; Hilgers J; Servaas J; Poels L; Thomas C; Kenemans P
Int J Cancer Suppl; 1988; 3():61-7. PubMed ID: 3209301
[TBL] [Abstract][Full Text] [Related]
22. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
24. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer.
Yoshimura M; Nishimura R; Murotani A; Miyamoto Y; Nakagawa T; Hasegawa K; Koizumi T; Shii K; Baba S; Tsubota N
Cancer; 1994 Jun; 73(11):2745-52. PubMed ID: 7514953
[TBL] [Abstract][Full Text] [Related]
25. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
[TBL] [Abstract][Full Text] [Related]
26. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
27. [Urinary gonadotropin fragment measurement in the monitoring of trophoblastic disease].
Fu CY; Cole LA; Kardana A
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):475-7, 510-1. PubMed ID: 7835119
[TBL] [Abstract][Full Text] [Related]
28. Pros and cons of gynecologic tumor markers.
Bast RC; Hunter V; Knapp RC
Cancer; 1987 Oct; 60(8 Suppl):1984-92. PubMed ID: 2443235
[TBL] [Abstract][Full Text] [Related]
29. Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers.
Kinugasa M; Nishimura R; Koizumi T; Morisue K; Higashida T; Natazuka T; Nakagawa T; Isobe T; Baba S; Hasegawa K
Jpn J Cancer Res; 1995 Aug; 86(8):783-9. PubMed ID: 7559103
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
Durdević S; Segedi D; Vejnović T; Radeka G
Med Pregl; 1992; 45(7-8):262-5. PubMed ID: 1344453
[TBL] [Abstract][Full Text] [Related]
31. The purification and development of a radioimmunoassay for beta-core fragment of human chorionic gonadotrophin in urine: application as a marker of gynaecological cancer in premenopausal and postmenopausal women.
Lee CL; Iles RK; Shepherd JH; Hudson CN; Chard T
J Endocrinol; 1991 Sep; 130(3):481-9. PubMed ID: 1719119
[TBL] [Abstract][Full Text] [Related]
32. [The present and the future of tumor markers].
Nozawa S
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Aug; 43(8):883-9. PubMed ID: 1680941
[TBL] [Abstract][Full Text] [Related]
33. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
[TBL] [Abstract][Full Text] [Related]
34. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
35. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
36. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
37. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
[TBL] [Abstract][Full Text] [Related]
38. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive measurement to CA 125 marker found.
Oncology (Williston Park); 1991 Dec; 5(12):64. PubMed ID: 1840026
[No Abstract] [Full Text] [Related]
40. Clinical utility of CA 125 in preoperative diagnosis of patients with pelvic masses.
Finkler NJ
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):105-7. PubMed ID: 8365503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]